Diagonal Therapeutics

📍 Watertown, United States🗓 Founded 2022👥 31 employees💰 Last funded Jan 2026
Biotechnology🌐 diagonaltx.com
Website LinkedIn
Diagonal Therapeutics is developing a new class of clustering antibody medicines designed to address the root causes of severe genetic diseases. Using our DIAGONAL platform, we engineer clustering bispecific antibodies to restore healthy cell signaling in genetically driven diseases. This innovative approach offers potential therapies that can modify disease biology, providing lasting benefits for patients with limited treatment options. Our lead program, DIAG723, targets hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH), two serious vascular diseases with significant unmet needs. It focuses on the dysregulated signaling that contributes to both conditions, showing promising results in early models. With strong investor support and a growing clinical pipeline, Diagonal Therapeutics is redefining treatment possibilities for challenging genetic diseases, moving beyond symptom relief to disease modification. Learn more at: www.diagonaltx.com
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2022
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Diagonal Therapeutics?
Diagonal Therapeutics has 1 investors on record on gritt.io, 1 mid-stage.
When did Diagonal Therapeutics last raise funding?
The most recent investment in Diagonal Therapeutics recorded on gritt.io was in January 2026.
When was Diagonal Therapeutics founded?
Diagonal Therapeutics was founded in 2022.
What industry is Diagonal Therapeutics in?
Diagonal Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Diagonal Therapeutics based?
Diagonal Therapeutics is headquartered in Watertown, United States.